Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Value Score - The Value Score identifies attractive and discounted stocks using ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors [3] Growth Score - The Growth Score emphasizes a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [4] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing factors like one-week price changes and monthly earnings estimate changes to identify optimal buying times [5] VGM Score - The VGM Score combines the three Style Scores to highlight companies with the best value, growth forecasts, and momentum, serving as a strong indicator alongside the Zacks Rank [6] Zacks Rank - The Zacks Rank is a proprietary model based on earnings estimate revisions, aiding investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988 [7][8] Stock to Watch: Henry Schein Inc. - Henry Schein Inc. is a leading global distributor of healthcare products and services, operating in 33 countries and serving various healthcare practitioners [11] - Currently rated 3 (Hold) on the Zacks Rank, Henry Schein has a VGM Score of A and a Value Style Score of A, with a forward P/E ratio of 15.06, indicating attractive valuation metrics [11][12] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate increasing by $0.02 to $4.86 per share for fiscal 2025, and an average earnings surprise of 2.4% [12]

Company Overview - Henry Schein Inc. is a leading distributor of health care products and services globally, serving various practitioners including dental, medical, and animal health sectors, as well as government and institutional health care clinics [11] - The company operates in 33 countries [11] Investment Ratings - Henry Schein is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [11] - The Growth Style Score for HSIC is B, forecasting a year-over-year earnings growth of 2.5% for the current fiscal year [12] Earnings Estimates - In the last 60 days, five analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.02 to $4.86 per share [12] - HSIC has an average earnings surprise of 2.4%, suggesting a history of exceeding earnings expectations [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, Henry Schein is positioned as a potential top pick for growth investors [12]

Group 1 - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, Equity Research reports, and Premium stock screens [1][2] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market over the next 30 days, based on three investment methodologies [2][3] Group 2 - Stocks are rated with an alphabetic system from A to F, where A indicates the highest potential for outperformance, and the Style Scores are categorized into Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] - The Value Score focuses on identifying undervalued stocks using various financial ratios, while the Growth Score emphasizes a company's financial health and future growth potential [3][4] - The Momentum Score assesses stocks based on price trends and earnings outlook, and the VGM Score combines all three styles to identify stocks with the best overall potential [5][6] Group 3 - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize returns, while stocks with lower ranks should be approached cautiously [9][10] Group 4 - Henry Schein Inc. is a leading global distributor of healthcare products and services, operating in 33 countries and serving various healthcare practitioners [11] - Currently rated 3 (Hold) by Zacks, Henry Schein has a VGM Score of A and a Growth Style Score of B, with a projected year-over-year earnings growth of 2.5% for the current fiscal year [11][12] - Recent upward revisions in earnings estimates and a solid earnings surprise average of 2.4% position Henry Schein as a potential growth investment [12]

Summary of Henry Schein Conference Call Company Overview - **Company**: Henry Schein - **Industry**: Medical Supplies and Devices - **Key Executives Present**: Stan Bergman (CEO), Ron South (CFO), Graham Stanley, Susan D'Onofrio (IR) Core Business Strategy - **BOLD Plus One Strategy**: - **B**: Build high growth, high margin businesses in specialty dental and medical products, targeting 50% of operating income from these by 2027 [4][5] - **O**: Optimize core distribution business for efficiency and customer satisfaction [5] - **L**: Leverage relationships with approximately 300 businesses to enhance sales across different product lines [6] - **D**: Digitalization of dentistry and medicine, including a new global e-commerce platform (GEP) [7][8] - **Plus One**: Advance relationships with suppliers, customers, and investors [9] Financial Performance - **Q1 Results**: Sales growth noted, with EPS growth excluding PPE impact [10][11] - **Earnings Growth Target**: High single digits to low double digits anticipated post-cyber incident recovery [11] Market Trends - **Dental Market**: Stable visit rates to dentists in the U.S., with a shift towards value in product selection [16][18] - **Equipment Stability**: Equipment sales stable, with some fluctuations; digital technology demand remains strong [18][21] - **International Markets**: Varying stability across Europe, with Brazil showing positive trends despite economic challenges [19][20] - **Software Demand**: Growth in software demand, transitioning to a SaaS model for recurring revenue [21][40] Long-term Financial Goals - **Earnings Growth**: Commitment to high single digit to low double digit growth, with 2026 guidance dependent on market momentum and restructuring initiatives [24][25] - **Cost Savings**: Expected $75 million to $100 million in cost savings from restructuring, leaning towards the higher end [25] Restructuring and Optimization - **Restructuring Focus**: Emphasis on optimizing endodontic business and leveraging synergies from acquisitions [28][29] - **Continuous Improvement**: Ongoing process to enhance efficiency and reduce costs, supported by KKR's investment [31] KKR Investment - **Strategic Partnership**: KKR holds approximately 15% stake, providing expertise in margin management and expense control [33][34] - **Negotiating Leverage**: KKR's portfolio may enhance negotiating power with suppliers [36] Capital Allocation Strategy - **M&A Activity**: Historical M&A spending of $300 million to $400 million annually, with a significant increase in 2023 [44] - **Share Repurchases**: $161 million in share repurchases in Q1, with a focus on maintaining a strong stock buyback strategy [46] Key Takeaways - **Misunderstood Aspects**: The effectiveness of the BOLD Plus strategy in driving growth and profitability through high-margin businesses and digital technology [48][49]

Company Overview - Henry Schein (HSIC) shares have increased by approximately 6.5% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Fresh estimates for Henry Schein have trended upward in the past month, indicating positive sentiment among analysts [2][4] - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the upcoming months [4] VGM Scores - Henry Schein has a Growth Score of B and a Momentum Score of B, with an overall VGM Score of A, placing it in the top quintile for investment strategies [3] Industry Performance - Henry Schein is part of the Zacks Medical - Dental Supplies industry, where Becton Dickinson (BDX) has seen a 3.3% increase in the past month [5] - Becton Dickinson reported revenues of $5.27 billion for the last quarter, reflecting a year-over-year growth of 4.5% [5] - For the current quarter, Becton Dickinson is expected to report earnings of $3.45 per share, a decrease of 1.4% from the previous year [6]

Summary of Henry Schein (HSIC) 2025 Conference Call Company Overview - **Company**: Henry Schein, Inc. (HSIC) - **Date of Conference**: May 29, 2025 - **Key Speakers**: Ron South (CFO), Andrea Albertini (CEO, Global Distribution and Technology), Tom Popack (CEO, Henry Schein Products Groups) Key Industry Insights - **Market Recovery**: After a slow January attributed to weather, there was a notable recovery in February and March, with positive trends observed in both dental and medical sectors [2][5][7] - **Regulatory Uncertainty**: The introduction of tariffs and regulatory changes has created uncertainty in the market, affecting customer navigation and supplier dynamics [4] - **Dental and Medical Stability**: The dental market remains stable, while the medical sector saw an uptick due to a late flu season, leading to increased sales of diagnostic kits [5] Core Business Initiatives - **Specialty Products Sales**: The distribution sales force is now selling specialty products, particularly in the endodontic business, which has shown strong market share and momentum [9][10][13] - **Implant Market Growth**: The company is experiencing mid to high single-digit growth in the implant market in Europe, while the U.S. market remains relatively flat due to macroeconomic conditions [20][22] - **Global E-commerce Platform**: A new e-commerce platform was launched in the UK and Ireland, with plans for a broader rollout in the U.S. and Canada in 2026. This initiative aims to enhance customer experience and operational efficiency [25][31] Financial Performance and Projections - **Long-term Growth Goals**: The company aims for 8% to 11% EPS growth, contingent on achieving 6% to 8% top-line growth, which is currently challenged by lower market growth rates in core dental and medical sectors [34][35] - **Restructuring Savings**: A restructuring plan initiated last year is expected to yield annual savings of $75 million to $100 million, contributing positively to the cost base by the end of 2025 [37] - **Technology Segment Growth**: The technology segment is expected to return to high single-digit growth, driven by the transition from on-premise to SaaS models, despite current low single-digit growth rates [44][46] Market Challenges and Opportunities - **DSO Relationships**: The company emphasizes the importance of strategic partnerships with Dental Service Organizations (DSOs) to drive profitability rather than engaging in price competition [56][58] - **Medical Segment Growth**: The medical business is projected to achieve a CAGR of 4% to 7%, with home solutions contributing significantly to this growth [61][62] - **KKR Involvement**: KKR's investment is expected to enhance operational efficiency and revenue enhancement initiatives, although it is still in the early stages of collaboration [63][64] Additional Insights - **Equipment Orders**: There is optimism regarding equipment orders, although macroeconomic concerns may lead to delays in installations and revenue recognition [40][41] - **Customer Experience Focus**: The company is working on improving customer experience through loyalty programs and targeted promotions, particularly for online shoppers [30][28] This summary encapsulates the key points discussed during the Henry Schein conference call, highlighting the company's performance, strategic initiatives, and market outlook.

Core Insights - The article discusses the recent earnings call for Henry Schein, Inc (NASDAQ: HSIC), a healthcare distribution company, highlighting the author's perspective on investment strategies and market conditions [1]. Company Overview - Henry Schein, Inc is positioned in the healthcare distribution sector, focusing on building financial assets for investors nearing retirement [1]. Investment Strategies - The author emphasizes the importance of having both long-term and short-term trading strategies, aiming for proper execution of trading plans and achieving absolute investing results [1]. Market Conditions - The article reflects an interest in utilizing inverse ETFs to capitalize on market declines, indicating a proactive approach to market volatility [1].

Summary of Henry Schein (HSIC) 2025 Conference Call Industry Overview - The discussion primarily revolves around the dental and medical supply industry, focusing on trends in dental demand and the company's performance in these sectors [3][4][5][6][36]. Key Points on Dental Market Trends - **January Softness**: January was noted as a soft month for dental demand, attributed to weather impacts and other market conditions [4][5]. - **Improvement in Demand**: February and March showed improvement in patient traffic, with April continuing this positive trend [5][6]. - **Demand vs. Supply**: There is a noted demand for dental services in the U.S. that exceeds supply, leading to an increase in dental office build-outs [6][7][10]. - **De Novo Build-Outs**: The rate of new dental office openings is higher than in previous years, driven by larger Dental Service Organizations (DSOs) recognizing the demand-supply gap [7][10][11]. - **Retirement of Dentists**: An increase in dentist retirements during the pandemic has contributed to the supply shortage [12][13]. Financial Guidance and Performance - **2025 Guidance**: The company maintained its revenue growth guidance of 2% to 4%, primarily driven by internal growth, despite foreign exchange headwinds [14][15][16]. - **Cost Management**: The company aims to achieve $75 million to $100 million in cost savings through restructuring initiatives [23][24]. Product and Service Innovations - **New Product Launches**: The company is focusing on new products like the TAPR Pro conical implant and technology products from Henry Schein One, which enhance customer engagement [19][20]. - **Home Solutions Growth**: The home solutions segment is growing at a high single-digit rate, with a significant acquisition (Ascentis) contributing to this growth [37][38]. Market Dynamics in Implants - **Implant Market Trends**: The U.S. implant market is relatively flat, with growth shifting towards value implants as general practitioners increasingly perform straightforward procedures [28][29][30]. - **Market Share Gains**: The company has gained market share in Europe, particularly in the premium implant segment [26][27]. Integration of Medical and Dental Services - **Shared Infrastructure**: Henry Schein has integrated its medical and dental businesses, sharing distribution centers and management teams, with about 25% to 30% common SKUs [40][41][42]. - **Crossover Services**: There is an increasing trend of community health centers offering both medical and dental services, enhancing cross-selling opportunities [43][44]. Strategic Partnerships and Future Outlook - **Collaboration with KKR**: The partnership with KKR is expected to enhance operational efficiency and provide insights into cross-selling opportunities [45][46][48]. - **Technology Adoption**: The company is focusing on increasing the adoption of its cloud-based systems (Dentrix Ascend) among its customer base, currently at about 10% penetration [49][50]. Conclusion - The company expresses optimism about the future, driven by increased dental office build-outs, strategic partnerships, and a focus on innovative products and services [52][53].

Core Insights - Henry Schein Inc. reported mixed financial results for the first quarter, with adjusted EPS of $1.15, a 4.5% increase year over year, surpassing the consensus estimate of $1.11. However, sales of $3.17 billion fell short of the consensus of $3.23 billion [1] - The company affirmed its 2025 adjusted EPS guidance of $4.80-$4.94, slightly above the consensus of $4.86, and anticipates sales growth of approximately 2%-4% over 2024, projecting sales between $12.43 billion and $13.18 billion, compared to a consensus of $13 billion [2] - Henry Schein expects its 2025 adjusted EBITDA to grow in the mid-single digits compared to 2024, with guidance assuming stable foreign currency exchange rates and no new tariffs [3] Analyst Ratings - Barrington Research analyst Michael Petusky maintained an Outperform rating on Henry Schein but reduced the price target from $90 to $86 [8] - Wells Fargo analyst Vik Chopra also maintained an Equal-Weight rating while lowering the price target from $80 to $75 [8]

Core Insights - Henry Schein reported $3.17 billion in revenue for Q1 2025, a slight year-over-year decline of 0.1% [1] - The EPS for the quarter was $1.15, up from $1.10 a year ago, indicating a positive trend in earnings [1] - The revenue fell short of the Zacks Consensus Estimate of $3.23 billion by 1.84%, while the EPS exceeded the consensus estimate of $1.11 by 3.60% [1] Revenue Performance - Geographic Revenue from International Dental Equipment was $197 million, below the average estimate of $209.20 million [4] - U.S. Distribution Revenue for Dental Equipment was $187 million, significantly lower than the estimated $232.79 million, reflecting a 25.4% decline year-over-year [4] - International Dental Merchandise revenue was $594 million, also below the estimate of $608.26 million [4] - U.S. Distribution Medical revenue was $1.03 billion, slightly above the estimate of $1.01 billion, showing a year-over-year increase of 1.6% [4] - International Dental revenue was $798 million, under the estimate of $824.47 million, with a year-over-year decline of 1.6% [4] - U.S. Distribution Dental Merchandise revenue was $591 million, exceeding the estimate of $569.68 million [4] - Global Specialty Products net sales were $367 million, slightly above the average estimate of $364.59 million [4] Stock Performance - Henry Schein's shares returned -0.3% over the past month, contrasting with the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]